A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
Eating smaller, more frequent meals can also promote the medications efficacy
These medications were initially created to treat type 2 diabetes and have been extensively researched for several decades
At Cantrell Schuette, our Dallas non-compete attorneys bring deep experience and a tailored approach to every case
Lifestyle and Commitment GLP-1 treatments are most effective when combined with lifestyle changes, such as a balanced diet and regular exercise